Tsutomu Furuse
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tsutomu Furuse has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
- Kenji Hashimoto
Basic Medicine Research Innovation Center for Cardiometabolic Diseases, Ministry of Education, Southwest Medical University, Luzhou, China
3 shared publications
Latest Publications
- Open Access
- 6 March 2010
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 9 (1) , 11
Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
Second-generation antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects (EPSs) than typical antipsychotic drugs, but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Although understanding of the pathophysiology of akathisia remains limited, it seems that a complex interplay of several neurotransmitter systems might play a role in its pathophysiology. The endoplasmic reticulum protein sigma-1 receptors are shown to regulate a number of neurotransmitter systems in the brain.
- 6 March 2010
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 9 (1) , 11
Open AccessFluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
Second-generation antipsychotic drugs have been reported to cause fewer incidences of extrapyramidal side effects (EPSs) than typical antipsychotic drugs, but adverse events such as akathisia have been observed even with atypical antipsychotic drugs. Although understanding of the pathophysiology of akathisia remains limited, it seems that a complex interplay of several neurotransmitter systems might play a role in its pathophysiology. The endoplasmic reticulum protein sigma-1 receptors are shown to regulate a number of neurotransmitter systems in the brain.
- Open Access
- 20 January 2010
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 9 (1) , 6
Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Delirium in older adults is a common and serious acute neuropsychiatric syndrome, with core features of inattention and global cognitive impairment. Although antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including sedation, extrapyramidal side effects, and cardiac arrhythmias.
- 20 January 2010
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 9 (1) , 6
Open AccessSigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
Delirium in older adults is a common and serious acute neuropsychiatric syndrome, with core features of inattention and global cognitive impairment. Although antipsychotic drugs are the medications most frequently used to treat this syndrome, these drugs are associated with a variety of adverse events, including sedation, extrapyramidal side effects, and cardiac arrhythmias.
- Open Access
- 21 December 2009
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 8 (1) , 26
Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
Psychotic depression is a clinical subtype of major depressive disorder. A number of clinical studies have demonstrated the efficacy of the combination of an antidepressant (for example, a tricyclic antidepressant or selective serotonin reuptake inhibitor (SSRI)) and an atypical antipsychotic or electroconvulsive therapy in treating psychotic depression. In some cases, the clinician or patient may prefer to avoid antipsychotic drugs altogether because of the risk of extrapyramidal side effects (EPS) in patients with psychotic depression treated with these drugs.
- 21 December 2009
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 8 (1) , 26
Open AccessFluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
Psychotic depression is a clinical subtype of major depressive disorder. A number of clinical studies have demonstrated the efficacy of the combination of an antidepressant (for example, a tricyclic antidepressant or selective serotonin reuptake inhibitor (SSRI)) and an atypical antipsychotic or electroconvulsive therapy in treating psychotic depression. In some cases, the clinician or patient may prefer to avoid antipsychotic drugs altogether because of the risk of extrapyramidal side effects (EPS) in patients with psychotic depression treated with these drugs.